scholarly journals Clinical And Epidemiologic Profile of Breast Cancer Differences In Mexico: A Retrospective Cohort Study From Guerrero.

2021 ◽  
Author(s):  
Azucena Ocampo-Bárcenas ◽  
Marlon De Ita Ley ◽  
Martín Morrugares-Ixtepan ◽  
Abril Bautista-Escutia ◽  
Ricardo Hernández-Morales ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Retrospective Cohort ◽  
Proportional Hazards Model ◽  
Ductal Carcinoma ◽  
Molecular Subtype ◽  
Locally Advanced ◽  
Cox Proportional Hazards Model ◽  
Breast Cancer Patients ◽  
Incidence And Mortality

Abstract Background: The regional disparities in Mexico impact the incidence and mortality of breast cancer (BC). Despite Guerrero state has a high grade of economic marginalization, it presents mortality lower than the national average. Clinical, pathological, and epidemiological assessment will help to understand the source of these differences.Objective: Describe the clinical, pathological, and overall survival of patients with BC from Guerrero and compare them with other reports from the Mexican population.Materials and Methods: Kaplan-Meier method was used to estimate overall survival time over a retrospective cohort of breast cancer patients treated at the Instituto Estatal de Cancerología “Dr. Arturo Beltrán Ortega (IECan) during 2010-2020. The Cox proportional hazards model was used to determine the prognosis factors.Results: A total of 923 women were included. 3.5% and 37.9% of patients were classified as Stage I and II; for locally advanced stages III and IV, it has been observed 36.1% and 14.3% of patients respectively. The most frequent histological type was ductal carcinoma (82.7%). The molecular subtype percentage found were HR+/HER2- (35.1%), HR±/HER2- (15.9%), HR±/HER2+ (14.4%), HR-/HER2+ (13.5%) and HR-/HER2 - (21%). The median follow-up was 49 months. Five-year survival for the entire cohort was 78% (95% CI, 73-82%), and 31% for metastatic disease (95% CI, 26.7-37.1%).Conclusion: The Guerrero state shares epidemiological parameters with other regions of Mexico; despite this, presents frequently one of the most aggressive molecular subtypes of breast cancer; so, the understanding of its lower mortality requires further analysis.

scholarly journals Assessment of prognostic factors in breast cancer in women in Senegal: a review of 288 cases

2021 ◽  
Vol 1 (1) ◽  
pp. 6-9
Author(s):  
Mamadou Ndiaye ◽  
Souleymane Dieng ◽  
Jaafar Thiam ◽  
Adja Coumba Diallo ◽  
Doudou Diouf ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Prognostic Factors ◽  
Hormone Receptors ◽  
Ductal Carcinoma ◽  
Locally Advanced ◽  
Public Health Problem ◽  
Major Public Health Problem ◽  
Advanced Stage ◽  
Breast Cancer Patients

INTRODUCTION: In Senegal, breast cancer is the second female cancer and poses a major public health problem. The aim of this work was to assess prognostic factors in the progression of breast cancer in women. PATIENTS AND METHODS: This is a retrospective study carried out over a period of one year from January 1, 2008 to December 31, 2008 on all the women followed for breast cancer in the oncology department at the Joliot Curie Institute. Thus, 288 breast cancer patients were collected. RESULTS: The average age of our patients was 47.32 years. The average parity was 4.9 children per woman. Twenty-two or 7% of patients had a history of cancer. Clinically, the tumor size was classified as T4 in 180 patients, ie 81%. Lymph node involvement in 188 patients (65.2%). The most frequent histological type was invasive ductal carcinoma with 90.3% of cases. A predominance of grades SBRII and SBRIII was observed (respectively 41% and 46%). Hormone receptors (RH) were positive in eight cases (24%). Overexpression of the HER2 gene was found in only four out of 30 patients. The limits of the surgery were specified in 48 patients with invaded margins in seven patients (14.5%). The presence of vascular emboli was noted in 18 patients among the 29 whose research was carried out in 179 patients, ie 62%. At the time of the initial diagnosis, 45 patients or 19.7% of patients presented at least one distant metastasis. The majority of patients were received at an advanced stage (89%, classified between stage III and IV). Only one patient was received at stage I. Overall survival for breast cancer was 72% at 3 years and 30% at 5 years. The 5-year overall survival of patients with localized disease was 85% compared to 5% for patients with advanced stage. CONCLUSION: The prognostic factors are multiple and often pejorative in our patients with a predominance of young women, locally advanced cancers and aggressive biological forms.

scholarly journals Postmenopausal Breast Cancer in Women, Clinical and Epidemiological Factors Related to the Molecular Subtype: A Retrospective Cohort Study in a Single Institution for 13 Years. Follow-Up Data

2020 ◽  
Vol 17 (23) ◽  
pp. 8722
Author(s):  
Cristina Marinela Oprean ◽  
Serban Mircea Negru ◽  
Dorel Ionel Popovici ◽  
Sorin Saftescu ◽  
Robert-Alexandru Han ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Molecular Subtype ◽  
Postmenopausal Breast Cancer ◽  
Living Environment ◽  
Molecular Characteristics ◽  
Southeastern Europe ◽  
Breast Cancer Patients

This study focused on the characteristics of postmenopausal breast cancer in the population of southeastern Europe. This retrospective study explored the clinical, epidemiological, and molecular characteristics of women with postmenopausal breast cancer. Material and methods: A retrospective cohort study was performed on 721 postmenopausal breast cancer patients selected from the database of our institution. The data collected consisted of age, living environment, location of the breast tumor, stage of the disease, and molecular sub-type. Patient characteristics were collected based on a systematic chart audit from medical records. The data were analyzed using SPSS 20.0 and Pearson analysis. Results: The most frequent age range for breast cancer diagnosis was 51 to 70 years old. Most of the patients (80.7%) came from an urban environment. The vast majority of patients were initially diagnosed in stage II (40.3%) and III (30.3%). The most frequent molecular sub-types were luminal B (39%) and luminal A (35.4%). Almost half of the breast tumors were located in the upper outer quadrant (48.8%). Conclusions: The results of this study describe the profile of patients in southeastern Europe within our institution diagnosed with postmenopausal breast cancer. In our study, patients were first diagnosed with more advanced stages of breast cancer compared with other European countries.

Breast cancer in young women less than 30 years from southern India: Study on clinical profile and outcome

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22196-e22196
Author(s):  
R. Rejiv ◽  
D. Biswajit ◽  
R. Neelesh ◽  
V. Sridevi ◽  
T. G. Sagar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Ductal Carcinoma ◽  
Locally Advanced ◽  
Young Patients ◽  
Stage Iv ◽  
Radical Mastectomy ◽  
Reproductive Age ◽  
Breast Cancer Patients ◽  
Pregnancy And Lactation

e22196 Background: Breast cancer in young patients have an aggressive behaviour with poorer outcome. The patients are in their reproductive age group and are concerned with fertility issues,pregnancy and lactation. The literature pertaining to patients less than 30 years is limited. Methods: 213 Patients under the age of 30 years with breast cancer were studied for Demographics, clinical presentations, pathological profiles, treatment and survival. The case records were retrospectively analyzed between Jan 1993 - Dec 2003 at Cancer Institute (WIA) Chennai. Results: The mean age of the study population was 28 years and ranged between 17 to 30 years. Early menarche, defined as less than 12 years (17.5 %), Nulliparity (21.1%), first child birth less than 18 years (26.8%) were the major risk factors noted. Family history of breast and ovarian cases were seen in 6.6% of the patients. The Stage distribution included Stage I (1.4%), Stage II (31%), Stage III (49.6) and Stage IV (11%) and unclassifiable (7%). Node positive tumours constituted 158 patients (74.1%). Hormone receptor studies were negative in 62% of the patients. Modified radical mastectomy was performed in 164 (77%) of the patients. Non infiltratring ductal carcinoma histopathology was noted in 13.6%. Surgical and radiocastration was performed in 35.2% and 17% of the cases respectively. Of 201 (94.3%) patients who received chemotherapy anthracycline based chemotherapy was delivered in 30.3%. Recurrence pattern included local, local and distant and distant recuurences in 8.5%, 23.5% and 2.3% respectively. The 5 year over all survival for the evaluable patients was 53.2%. Conclusions: Very young Indian patients less than 30 years constitute a unique subset of breast cancer patients with majority being hormone receptor negative and locally advanced stage at presentation. The over all outcome is inferior compared to older patients with breast cancer. More aggressive adjuvant treatment may help in improving survival. No significant financial relationships to disclose.

BOLERO-2: Health-related quality-of-life (HRQoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane.

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 125-125 ◽  
Author(s):  
Hope S. Rugo ◽  
J. Thaddeus Beck ◽  
José Baselga ◽  
Shinzaburo Noguchi ◽  
Michael Gnant ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Proportional Hazards Model ◽  
Performance Status ◽  
Metastatic Breast ◽  
Cox Proportional Hazards Model ◽  
Phase Iii ◽  
Sensitivity Analyses ◽  
Rank Test ◽  
Breast Cancer Patients

125 Background: BOLERO-2, a phase III study, randomized 724 patients with hormone-receptor–positive metastatic breast cancer, who had recurrence or progression on/after prior nonsteroidal aromatase inhibitor therapy, to everolimus (EVE) + exemestane (EXE) or EXE + placebo. A preplanned 12-mo median time interim analysis demonstrated that EVE + EXE significantly improved progression-free survival (PFS) vs EXE + placebo, but EVE + EXE resulted in a higher rate of grade 3-4 toxicity. Per-protocol patients reported HRQoL data are limited; here we report on additional post hoc analyses of these outcomes. Methods: Using the EORTC QLQ-C30 questionnaire, HRQoL was assessed at baseline and every 6 weeks thereafter until progression. QLQ-C30 consists of 30 items combined into 15 subscales, including a Global Health Status (GHS), where higher scores (range, 0-100) indicate better HRQoL. Analysis included a protocol-specified time to definitive deterioration (TTD) analysis at a 5% decrease in QoL relative to baseline, with no subsequent increase above this threshold. We report additional sensitivity analyses using 10-point minimally important difference (MID) decreases in QLQ-C30 score relative to baseline. Treatment arms were compared using a stratified log-rank test and a Cox proportional hazards model adjusted for trial stratum (visceral metastases and previous hormone sensitivity), age, sex, race, baseline score, ECOG performance status, prognostic risk factors, and treatment history. Results: Baseline QLQ-C30 GHS scores were not statistically significantly different across treatment groups (64.7 vs 65.3; difference –0.7 [95% CI, –4.3-3.0]). Median TTD in HRQoL was 7.0 mo (95% CI, 5.6-8.3) for EVE + EXE vs 5.6 (95% CI, 4.2-7.0) for EXE (p = .0792). Adjusted HR (0.80) approached significance (95% CI, 0.63-1.02). At the 10-point MID, median TTD for EVE + EXE was 9.7 mo (95% CI, 8.3-11.2) vs 8.4 mo (95% CI, 6.3-12.5) for EXE. Adjusted HR was 0.90 (95% CI, 0.69-1.18). Conclusions: These additional analyses from the BOLERO-2 study demonstrate that in addition to significantly improving PFS, EVE + EXE does not compromise HRQoL.

Proliferation-based prediction for overall survival in locally advanced HER2(+) breast cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12007-e12007
Author(s):  
Manuel Pedregal ◽  
Federico Rojo ◽  
Cristina Carames Sanchez ◽  
Francisco Lobo ◽  
Yann Izarzugaza ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Locally Advanced ◽  
Luminal Breast Cancer ◽  
Breast Cancer Patients ◽  
Ki67 Expression ◽  
Her2 Breast Cancer

e12007 Background: Breast cancer prognosis is influenced by several factors including Ki67 expression which may have a predictive role in luminal breast cancer patients. The aim of this study was to assess the value of Ki67 in breast cancers with positive hormonal receptors and HER2 overexpressed and to evaluate its impact on survival. Methods: Seventy eight consecutive patients diagnosed with locally advanced HER2 positive breast cancer who were treated with adjuvant therapy based on HER2 treatment were selected for this study (2004-2014). The adjuvant chemotherapy schemes were 44% TCH, 16% FEC, 11% AC/T and 29% other therapies. The median of followup was 68 months. Tumor proliferation was assessed immunohistochemically by Ki67 expression and calculated as percentage of stained tumor cells from this cohort previous to adjuvant chemotherapy administration and the results obtained were correlated with disease status and outcome. Results: High proliferation defined as a percentage > 15 of tumor cells was observed in 69% of the breast cancer patients cases. High proliferation significantly predicted longer overall survival (OS) (Log rank 0,012). At 10 years of follow-up, 93% of the patients with KI67 high expression were alive versus 43% of patients without overexpression. Multivariate analysis confirmed the clinical significance of Ki67 predicting OS for luminal HER2 breast cancer patients (p 0,04 y HR 9,6). Conclusions: High proliferation identifies a setting of luminal-B HER2+ subtype breast cancer patients with a significantly longer overall survival.

A prognostic nomogram for predicting recurrence and survival in rectal cancers without neoadjuvant treatment.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 555-555
Author(s):  
Junjie Peng ◽  
Ying Ding ◽  
Hongbin Wu ◽  
Sanjun Cai
Keyword(s):  
Overall Survival ◽  
Proportional Hazards Model ◽  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Cox Proportional Hazards ◽  
Cox Proportional Hazards Model ◽  
Adjuvant Chemoradiotherapy ◽  
Preoperative Treatment ◽  
7Th Edition ◽  
Rectal Cancers

555 Background: To develop a prognostic nomogram for predicting recurrence and survival in patients with locally advanced rectal cancers that were not able to receive preoperative treatment. Methods: A total of 887 patients with AJCC (7th edition) stage II-III rectal cancers were retrospectively collected from a single institution. All patients did not receive any preoperative treatment before curative resection of the primary tumor. Cox proportional hazards model was performed to develop the predictive model for OS. Results: The 5-year local recurrence rate, distant metastases rate, and overall survival rate were 22.2%, 32.9%, and 63.9%, respectively. A prognostic nomogram was successfully developed to predicting patients’ 5-year overall survival, with a concordance index of 0.7. Factors in this model included patients’ age, gender, CEA value, tumor location, T stage, N stage, metastatic lymph nodes ratio, lymphvascular invasion, perineural invasion, adjuvant chemotherapy, adjuvant chemoradiotherapy. Our nomogram improved the predicting accuracy of current AJCC stage system (7th edition). Conclusions: The prognostic nomogram integrated patients demographic and clinicopathologic factors, which is better able to account for tumor and patient heterogeneity. Our individualized prediction nomogram could help physicians counsel and advise patients about their personalized treatment strategies and follow-up protocols. [Table: see text]

Association of radiation therapy with overall survival in patients undergoing surgery for T3N0M0 adenocarcinoma of the rectum.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 528-528
Author(s):  
David Mitchell Marcus ◽  
Dana Nickleach ◽  
Bassel F. El-Rayes ◽  
Jerome Carl Landry
Keyword(s):  
Overall Survival ◽  
Radiation Therapy ◽  
Proportional Hazards ◽  
Proportional Hazards Model ◽  
Locally Advanced ◽  
Multivariable Analysis ◽  
Cox Proportional Hazards ◽  
Cox Proportional Hazards Model ◽  
Entire Cohort ◽  
The Impact

528 Background: The standard treatment for locally advanced rectal cancer is neoadjuvant chemoradiation followed by surgery, but many physicians question the benefit of multimodality therapy in patients with stage T3N0M0 disease. We aimed to determine the impact of radiation therapy (RT) on overall survival (OS) in this group of patients. Methods: We used the Surveillance, Epidemiology, and End Results database to identify patients undergoing surgery for T3N0M0 adenocarcinoma of the rectum from 2004 to 2010. The Kaplan-Meier method was used to compare OS for patients receiving RT vs. no RT, along with for pre-op vs. post-op RT among patients that received RT. Multivariable analysis (MVA) using a Cox proportional hazards model was performed to assess the association of RT with OS after adjusting for patient age, gender, race, tumor grade, carcinoembryonic antigen, type of surgery, and circumferential margin status. The analysis was repeated separately on patients that underwent total colectomy (TC) vs. sphincter-sparing surgery. Results: The cohort included 8,679 patients, including 4,705 who received RT and 3,974 who did not. Median age was 66 years. Five year OS was 76.5% in patients who received RT, compared to 60.0% in patients who did not receive RT (p <0.001). Five year OS was 76.9% for patients receiving pre-op RT vs. 75.7% in patients receiving post-op RT (p = 0.247). In patients undergoing TC, five year OS was 74.7% for patients receiving RT, compared to 47.5% in patients not receiving RT (p <0.001). In patients undergoing sphincter-sparing surgery, five year OS was 77.7% in patients receiving RT, compared to 62.9% in patients not receiving RT (p <0.001). Use of RT was significantly associated with OS on MVA, both in the entire cohort (HR 0.70 [95% CI 0.60-0.81]; p<0.001) and in subsets of patients undergoing TC (HR 0.55 [95% CI 0.38-0.79]; p=0.001) and sphincter-sparing surgery (HR 0.70 [95% CI 0.59-0.84]; p<0.001). Conclusions: The use of RT is associated with superior OS in patients undergoing surgery for T3N0M0 adenocarcinoma of the rectum. This benefit is demonstrated in both the pre-op and post-op settings and applies to patients undergoing both TC and sphincter-sparing surgery.

Clinical utility of SERUM extracelullar domain of HER2 receptor (ECD) in HER2-positive breast cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e12086-e12086
Author(s):  
Ariadna Gasol Cudós ◽  
Serafin Morales Murillo ◽  
Joel Veas Rodriguez ◽  
Carles Canosa Morales ◽  
Jordi Melé Olivé ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Locally Advanced ◽  
Pathologic Complete Response ◽  
Response To Treatment ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Metastatic Setting ◽  
Positive Breast Cancer

e12086 Background: Although ECD expression was validated as tumor marker years ago, it is not used in daily clinical practice even if a prognostic value was demonstrated in some trials. Methods: In our single institution, during January 2013-2019, ECD was analyzed in a series of HER2 positive breast cancer patients; 71 in early or locally-advanced and 45 in metastatic setting. Results: In the metastatic cohort, median ECD expression was of 28 ng/ml (6,5-350), thus 10 (22%) patients had lower levels than threshold of 15ng/ml. No correlation was found between ECD expression and other clinicopathological variables. No association was found with overall survival however in patients with metastases at diagnosis higher ECD expression was correlated with a short overall survival (25 vs 54 months). Higher levels of ECD decreased according to good response to treatment. Median ECD expression was of 12ng/ml (3,6-97) in non-metastatic setting, however only 11 (15%) patients had elevated levels ( > 15ng/ml). Estrogen receptor and ki67 expression were not correlated with ECD levels. Median ECD expression in tumors > 5cm was 21,87 ng/ml versus 12ng/ml in smaller tumors (p = 0,006); in nodal involvement median ECD was 16,77 ng/ml versus 12,05 without affectation (p = 0,09). Patients with ECD higher than 10 ng/ml had a 55% pathologic complete response (pCR) versus 25% if less than 10ng/ml (OR 3.68, p = 0.027). Interestingly, none of tumors > 5cm and ECD < 10ng/ml achieved a pCR. Conclusions: Higher levels of ECD were observed in the metastatic setting and their decreased levels during treatment was correlated with response. In early and locally-advanced setting higher levels were found in larger tumors; and also these tumors had better response than lower levels of ECD. ECD could be used as a monitoring tool in the metastatic scenario and as a predictive factor of response in the neoadjuvant setting, specifically in tumors > 5cm.

Sign in / Sign up

Export Citation Format

Share Document